Key result
St. Jude aortic valve replacement carries a ~37% lifetime bleeding risk in 75-year-old men.
Population
2986 patients from 8 studies undergoing primary isolated aortic valve replacement with St. Jude Medical…
Design
Meta-analysis
Follow-up
16,163 patient-years
Authors
Loading...
Age-specific risks highlight bleeding hazard in elderly post-AVR; extends microsimulation modeling to guide personalized anticoagulation and trials.
Meta-Analysis (n=2,986)
Meta-analysis combined with microsimulation provides age-specific estimates of life expectancy and lifetime risks of thromboembolic and bleeding events after AVR with St. Jude Medical prostheses, emphasizing the need for optimal INR control.
Johanna J.M. Takkenberg (2001) conducted a meta-analysis in Primary isolated aortic valve replacement (n=2,986). Aortic valve replacement with St. Jude Medical prostheses was evaluated on Postoperative valve-related events (thromboembolic and bleeding events). Aortic valve replacement with St. Jude Medical prostheses in males aged 35 and 75 years yielded lifetime risks of 22% and 7% for thromboembolic events, and 15% and 37% for bleeding events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: